Thursday 26th April 2018
|Text too small?|
ASX-listed Volpara Health Technologies is in a trading halt while the Kiwi digital health firm raises capital from institutional investors ahead of next week's quarterly cash flow report.
Wellington-based Volpara, which focuses on early detection of breast cancer using artificial intelligence, sought a trading halt on the ASX today to let company raise money through an institutional placement "in an orderly manner", it said in a statement. The placement is part of a proposed capital raising, which will also include a share purchase plan for existing investors.
The shares last traded at 69 Australian cents, and while they've dipped 1.4 percent so far this year, the stock is still trading above its 2016 initial public offering price of 50 cents.
The halt will lift once Volpara announces the outcome of the placement or when trading opens on Monday.
The company this month said it beat its goal of lifting annual recurring revenue 200 percent in the March 2018 year, with ARR at $3.6 million as at March 31. Volpara is scheduled to release its quarterly cash flow statement and hold an investor briefing on April 30. It had cash on hand of $7 million as at Dec. 31.
No comments yet
NZ dollar rises on optimism for China-US trade deal
Steel & Tube recovery to include $5.6M of 2nd-half cost savings
Open Country challenges validity of Fonterra's 2018 milk price
Guest night growth slows; overseas visitors spent less time in North Island
Nib NZ first-half earnings slide 30% as claims outpace policy growth
Customer satisfaction in NZ banks rises despite Australian scandals
Perky services sector in Janary soothes fears over cooling economy
PFI doubles 2018 profit on valuation gains, underlying earnings fall short
Steel & Tube turnaround continues with 49% jump in first-half net profit
February 18th Morning Report